Dipeptidyl peptidase-4 inhibitors (DPP-4i) prolong the activity of GLP-1 by inhibiting its catabolism and should be used with adjusted dosage regimens in DKD patients. This evidence concerns the gene GLP1R and diabetic kidney disease.